EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Vergleichsstudie

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Gabe S Sonke iD, Annemiek van Ommen-Nijhof iD, Noor Wortelboer iD, Vincent van der Noort, Astrid C P Swinkels iD, Hedwig M Blommestein iD, Cristina Guerrero Paez, Linda Mol, Aart Beeker, Karin Beelen, Lisanne C Hamming, Joan B Heijns und 11 weitere

Nature · 12.12.2024 · 636 (8042) · 474-480

DOI: 10.1038/s41586-024-08035-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nature, online erschienen am 27.11.2024. Verfasst von Gabe S Sonke und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. g.sonke@nki.nl. Hauptthemen laut MEDLINE: Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: CADTH, ZIN and Medical Delta, Novartis and Gilead.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in combination with endocrine therapy improve the outcomes of patients with hormone-receptor (HR)-positive, HER2-negative advanced breast cancer and can be used early as first-line treatment or deferred to second-line treatment1-7. Randomized data comparing the use of CDK4/6i in the first- and second-line setting are lacking. The phase 3 SONIA trial (NCT03425838) randomized 1,050 patients who had not received previous therapy for advanced breast cancer to receive CDK4/6i in the first- or second-line setting8. All of the patients received the same endocrine therapy, consisting of an aromatase inhibitor for first-line treatment and fulvestrant for second-line treatment. The primary end point was defined as the time from randomization to disease progression after second-line treatment (progression-free survival 2 (PFS2)). We observed no statistically significant benefit for the use of CDK4/6i as a first-line compared with second-line treatment (median, 31.0 versus 26.8 months, respectively; hazard ratio = 0.87; 95% confidence interval = 0.74-1.03; P = 0.10). The health-related quality of life was similar in both groups. First-line CDK4/6i use was associated with a longer CDK4/6i treatment duration compared with second-line use (median CDK4/6i treatment duration of 24.6 versus 8.1 months, respectively) and more grade ≥3 adverse events (2,763 versus 1,591, respectively). These data challenge the need for first-line use of a CDK4/6i in all patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsTime-to-TreatmentAgedFemaleHumansMiddle AgedAntineoplastic Agents, HormonalAromatase InhibitorsDisease ProgressionEstrogen Receptor AntagonistsFulvestrantNeoplasm StagingProgression-Free SurvivalQuality of Life

Substanzen

Antineoplastic AgentsAntineoplastic Agents, HormonalAromatase InhibitorsCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Estrogen Receptor AntagonistsFulvestrantProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. g.sonke@nki.nl.
  • Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
  • Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Clinical Research Department, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
  • Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.

ORCID-Profile: Gabe S Sonke, Annemiek van Ommen-Nijhof, Noor Wortelboer, Astrid C P Swinkels, Hedwig M Blommestein, Aafke H Honkoop, A Elise van Leeuwen-Stok, Agnes Jager

Förderung

  • CADTH, ZIN and Medical Delta
  • Novartis and Gilead

Zitieren

APA

Sonke, G. S., van Ommen-Nijhof, A., Wortelboer, N., van der Noort, V., Swinkels, A. C. P., Blommestein, H. M., Guerrero Paez, C., Mol, L., Beeker, A., Beelen, K., Hamming, L. C., Heijns, J. B., Honkoop, A. H., de Jong, P. C., van Rossum-Schornagel, Q. C., van Schaik-van de Mheen, C., Tol, J., Tromp-van Driel, C. S., Vrijaldenhoven, S., …, & SONIA Study Consortium (2024). Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer. Nature, 636(8042), 474-480. https://doi.org/10.1038/s41586-024-08035-2

Vancouver

Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, et al. Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer. Nature. 2024;636(8042):474-480. doi:10.1038/s41586-024-08035-2

BibTeX
@article{Sonke2024,
  author = {Sonke, Gabe S and van Ommen-Nijhof, Annemiek and Wortelboer, Noor and van der Noort, Vincent and Swinkels, Astrid C P and Blommestein, Hedwig M and Guerrero Paez, Cristina and Mol, Linda and Beeker, Aart and Beelen, Karin and Hamming, Lisanne C and Heijns, Joan B and Honkoop, Aafke H and de Jong, Paul C and van Rossum-Schornagel, Quirine C and van Schaik-van de Mheen, Christa and Tol, Jolien and Tromp-van Driel, Cathrien S and Vrijaldenhoven, Suzan and van Leeuwen-Stok, A Elise and Konings, Inge R and Jager, Agnes and SONIA Study Consortium, SONIA Study Consortium},
  title = {Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer},
  journal = {Nature},
  year = {2024},
  volume = {636},
  number = {8042},
  pages = {474--480},
  doi = {10.1038/s41586-024-08035-2}
}
Kostenlos starten →